Post

Two-day ‘India Pharma 2026’ concludes with strong call for enhanced funding, infrastructure and speed to drive pharmaceutical innovation India must proactively position itself in the evolving global pharmaceutical landscape to remain competitive and relevant: Joint Secretary, Department of Pharmaceuticals Over 800 delegates, 60 national and international speakers attended 10 sessions NEW DELHI, 14 April 2026: The 9th edition of ‘India Pharma 2026’, the flagship event of Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt of India, today concluded after two days of extensive deliberations on strengthening India’s pharmaceutical and biopharma ecosystem. The event witnessed participation from over 800 delegates, with more than 60 speakers engaging across 10 sessions, supported by over 20 partner organisations, reflecting the growing importance of the platform in shaping the sector’s future trajectory. Delivering the valedictory address, Mr Satyaprakash T L, Joint Secretary, Department of Pharmaceuticals Ministry of Chemicals and Fertilizers, Govt of India, said that discussions across sessions converged around three critical enablers for the next phase of growth—funding, infrastructure and speed. While stakeholders expressed views on prioritisation, there was a shared understanding that coordinated action across government, industry and academia is essential. Emphasising the urgency of collaboration, Mr Satyaprakash noted that India must proactively position itself in the evolving global pharmaceutical landscape to remain competitive and relevant. Reflecting on the broader evolution of India’s biotechnology and pharmaceutical ecosystem, Dr Renu Swarup, Former Secretary to Govt of India, Department of Biotechnology, Ministry of Science & Technology while addressing session on ‘Reflections and Big Moves to Leapfrog Innovation’, emphasised that the country has made significant strides in building a comprehensive innovation value chain over the past decade, spanning discovery, development and deployment. India has successfully strengthened linkages between academia and industry, which were earlier fragmented, and has created a more cohesive ecosystem for product development. Drawing on the experience of the COVID-19 pandemic, she described it as a testbed that validated India’s capabilities in areas such as financing, partnerships, infrastructure and rapid innovation. India’s bioeconomy, she added, has already surpassed earlier targets and reached approximately $195 billion, underscoring the sector’s growth momentum and future potential.